Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Marie-Thérèse
Marie-Thérèse Le Dall, Genevilliers FR
| Patent application number | Description | Published |
|---|---|---|
| 20100041115 | PRODUCTION OF DICARBOXYLIC ACIDS BY IMPROVED MUTANT STRAINS OF YARROWIA LIPOLYTICA - The invention concerns a method for producing dicarboxylic acids (DCA) with long hydrocarbon chains, also called diacids, which consists in culturing a mutant strain of | 02-18-2010 |
Marie-Thérèse Le Dall, Genevilliers FR
| Patent application number | Description | Published |
|---|---|---|
| 20100041115 | PRODUCTION OF DICARBOXYLIC ACIDS BY IMPROVED MUTANT STRAINS OF YARROWIA LIPOLYTICA - The invention concerns a method for producing dicarboxylic acids (DCA) with long hydrocarbon chains, also called diacids, which consists in culturing a mutant strain of | 02-18-2010 |
Marie-Thérèse Paternostre, Verrieres Le Buisson FR
| Patent application number | Description | Published |
|---|---|---|
| 20110178013 | NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THE THERAPEUTIC USE THEREOF - The present invention relates to novel octapeptide compounds of general formula (I): H-2-Nal | 07-21-2011 |
Marie-Thérèse Simon-Gage-Soufflot, Chaville FR
| Patent application number | Description | Published |
|---|---|---|
| 20110144036 | HIP/PAP Polypeptide Composition for Use in Liver Regeneration and for the Prevention of Liver Failure - This invention is based on the experimental finding that HIP/PAP has mitogenic and antiapoptotic effects in vitro on hepatocytes in primary culture. Moreover, HIP/PAP is a mitogenic and anti-apoptotic molecule for hepatocytcs, in vivo, during liver failure and liver regeneration. The present invention is also based on the experimental finding that HIP/PAP administration has no adverse effects in mammals. This invention concerns a pharmaceutical composition for stimulating liver regeneration in vivo including after chronic/acute liver failure, comprising an effective amount of a polypeptide comprising an amino acid sequence having 90% amino acid identity with the polypeptide consisting of the amino acid sequence starting at the amino acid residue (36) and ending at the amino acid residue (175) of sequence SEQ ID No 1, in combination with at least one physiologically acceptable excipient. | 06-16-2011 |